According to a report by Malaya on June 4, Philippine Senator Joel Villanueva called for a review of Senate Bill 11990, also known as the "Vaporized Nicotine and Non-Nicotine Products Regulation Act," in order to transfer regulatory authority over e-cigarette products to the Food and Drug Administration (FDA) instead of the Department of Trade and Industry (DTI).
The legislator stated that despite the official implementation of Bill 11990 in 2022, amendments are urgently needed due to the increasing health issues related to e-cigarettes. Additionally, the Ministry of Trade and Industry's efficiency in banning illegal e-cigarette shops is low and needs to be addressed immediately.
I support the FDA's investigation into this matter and its regulation. There are issues with the enforcement or implementation of this law. The issue should be resolved by the FDA instead of the DTI.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
